| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.5 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.5 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.021 | 0.5 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | 0.02 | 0.5 |